Literature DB >> 28815336

Treatment selection in oropharyngeal cancer: a surveillance, epidemiology, and end results (SEER) patterns of care analysis.

Nitin A Pagedar1, Catherine Chioreso2, Jennifer A Schlichting2, Charles F Lynch2,3, Mary E Charlton2.   

Abstract

PURPOSE: Treatment for oropharyngeal cancer (OPC) has changed over the past two decades under multiple influences. We provide a population-based description of the application of radiotherapy, surgery, and chemotherapy to OPC in 1997, 2004, and 2009.
METHODS: The National Cancer Institute's Patterns of Care study for OPC included multiple variables not available in the public-use dataset. We identified factors correlating with selection of primary surgery versus radiotherapy with or without chemotherapy (RTC) and analyzed predictors of all-cause mortality. We estimated the frequency of human papillomavirus (HPV) testing.
RESULTS: RTC was more common in 2009 than in 1997, and was more commonly applied to Stage IV cases. However, RTC was not an independent risk factor for mortality compared with surgery. HPV status was known in 14% of patients in 2009.
CONCLUSIONS: RTC is the most common treatment for OPC, but it may not provide the best outcomes. HPV testing was uncommon in 2009.

Entities:  

Keywords:  Chemoradiotherapy; Human papillomavirus; Oropharyngeal neoplasm; Radiotherapy; Surgery

Mesh:

Year:  2017        PMID: 28815336      PMCID: PMC5771802          DOI: 10.1007/s10552-017-0938-3

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  31 in total

1.  Radiotherapy and concurrent chemotherapy: a strategy that improves locoregional control and survival in oropharyngeal cancer.

Authors:  A A Forastiere; A Trotti
Journal:  J Natl Cancer Inst       Date:  1999-12-15       Impact factor: 13.506

2.  Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.

Authors:  G Calais; M Alfonsi; E Bardet; C Sire; T Germain; P Bergerot; B Rhein; J Tortochaux; P Oudinot; P Bertrand
Journal:  J Natl Cancer Inst       Date:  1999-12-15       Impact factor: 13.506

3.  Treatment Outcomes for T4 Oropharyngeal Squamous Cell Carcinoma.

Authors:  Joseph Zenga; Michael Wilson; Douglas R Adkins; Hiram A Gay; Bruce H Haughey; Dorina Kallogjeri; Loren S Michel; Randal C Paniello; Jason T Rich; Wade L Thorstad; Brian Nussenbaum
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2015-12       Impact factor: 6.223

4.  A Contemporary Analysis of Surgical Trends in the Treatment of Squamous Cell Carcinoma of the Oropharynx from 1998 to 2012: A Report from the National Cancer Database.

Authors:  Erik Liederbach; Carol M Lewis; Katharine Yao; Bruce E Brockstein; Chi-Hsiung Wang; Waseem Lutfi; Mihir K Bhayani
Journal:  Ann Surg Oncol       Date:  2015-04-17       Impact factor: 5.344

5.  Patterns of care and perioperative outcomes in transoral endoscopic surgery for oropharyngeal squamous cell carcinoma.

Authors:  Jose P Zevallos; Nandita Mitra; Samuel Swisher-McClure
Journal:  Head Neck       Date:  2015-06-16       Impact factor: 3.147

6.  Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden.

Authors:  F Lewin; S E Norell; H Johansson; P Gustavsson; J Wennerberg; A Biörklund; L E Rutqvist
Journal:  Cancer       Date:  1998-04-01       Impact factor: 6.860

7.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.

Authors:  D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245

8.  Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue.

Authors:  Wolfgang Steiner; Oliver Fierek; Petra Ambrosch; Christian P Hommerich; Martina Kron
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-01

9.  Alcohol consumption and the risk of cancer: a meta-analysis.

Authors:  V Bagnardi; M Blangiardo; C La Vecchia; G Corrao
Journal:  Alcohol Res Health       Date:  2001

10.  Purposeful selection of variables in logistic regression.

Authors:  Zoran Bursac; C Heath Gauss; David Keith Williams; David W Hosmer
Journal:  Source Code Biol Med       Date:  2008-12-16
View more
  5 in total

1.  Treatment trends in head and neck cancer: Surveillance, Epidemiology, and End Results (SEER) Patterns of Care analysis.

Authors:  Jennifer A Schlichting; Nitin A Pagedar; Catherine Chioreso; Charles F Lynch; Mary E Charlton
Journal:  Cancer Causes Control       Date:  2019-05-22       Impact factor: 2.506

2.  Treatment trends in oropharyngeal carcinoma: Surgical technology meets the epidemic.

Authors:  T J Gal; Jon A Slezak; Alexandra E Kejner; Quan Chen; Bin Huang
Journal:  Oral Oncol       Date:  2019-08-14       Impact factor: 5.972

3.  Benefit from surgery with additional radiotherapy in N1 head and neck cancer at the time of IMRT: A population-based study on recent developments.

Authors:  Christoph Evers; Christian Ostheimer; Frank Sieker; Dirk Vordermark; Daniel Medenwald
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

Review 4.  Development of a prognostic model of overall survival in oropharyngeal cancer from real-world data: PRO.M.E.THE.O.

Authors:  Francesco Miccichè; Giuditta Chiloiro; Silvia Longo; Rosa Autorino; Mariangela Massaccesi; Jacopo Lenkowicz; Pierluigi Bonomo; Isacco Desideri; Liliana Belgioia; Almalina Bacigalupo; Elisa D'Angelo; Federica Bertolini; Anna Merlotti; Nerina Denaro; Pierfrancesco Franco; Francesco Bussu; Gaetano Paludetti; Umberto Ricardi; Vincenzo Valentini
Journal:  Acta Otorhinolaryngol Ital       Date:  2022-04-08       Impact factor: 2.618

5.  Prediction of survival in oropharyngeal squamous cell carcinoma using machine learning algorithms: A study based on the surveillance, epidemiology, and end results database.

Authors:  Su Il Kim; Jeong Wook Kang; Young-Gyu Eun; Young Chan Lee
Journal:  Front Oncol       Date:  2022-08-22       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.